about
Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysisS-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysisA phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinomaS-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1Molecular targeting to treat gastric cancer.S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysisPhase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: Phase II Study of S-1, S-1 plus CisFeasibility of oral administration of S-1 as adjuvant chemotherapy in gastric cancer: 4-week S-1 administration followed by 2-week rest vs. 2-week administration followed by 1-week restAbnormalities in the meibomian glands in patients with oral administration of anticancer combination drug-capsule TS-1(®): a case report.Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites.A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.Prognostic factors for stage IV gastric cancerChemotherapy for advanced gastric cancer: review of global and Japanese status.Targeted therapy in gastric cancer.S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis.Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trialCapecitabine in the treatment of esophageal and gastric cancers.S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.Targeting HER 2 and angiogenesis in gastric cancer.S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis.Interstitial lung disease caused by TS-1: a case of long-term drug retention as a fatal adverse reactionPredictive factors for ocular complications caused by anticancer drug S-1.Irinotecan Plus S-1 Followed by Hepatectomy for a Patient with Initially Unresectable Colorectal Liver Metastases, Who Showed Severe Drug Rash with Oxaliplatin Plus 5-FU and Leucovorin (FOLFOX).S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study.Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer.The prognostic significance of chemotherapy for stage IV gastric cancer patients: a single-institution experience.Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
P2860
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
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
S-1 in gastric cancer: a comprehensive review.
@ast
S-1 in gastric cancer: a comprehensive review.
@en
type
label
S-1 in gastric cancer: a comprehensive review.
@ast
S-1 in gastric cancer: a comprehensive review.
@en
prefLabel
S-1 in gastric cancer: a comprehensive review.
@ast
S-1 in gastric cancer: a comprehensive review.
@en
P1433
P1476
S-1 in gastric cancer: a comprehensive review.
@en
P2860
P2888
P356
10.1007/S10120-003-0232-9
P478
P577
2003-01-01T00:00:00Z